Royston, TX, United States
Royston, TX, United States

Time filter

Source Type

— Global Epinephrine Autoinjector Industry Report offers market overview, segmentation by types, application, countries, key manufactures, cost analysis, industrial chain, sourcing strategy, downstream buyers, marketing strategy analysis, distributors/traders, factors affecting market, forecast and other important information for key insight. Companies profiled in this report are Mylan, Sanofi, ALK Abello and Impax in terms of Basic Information, Manufacturing Base, Sales Area and Its Competitors, Sales, Revenue, Price and Gross Margin (2012-2017). Split by Product Types, with sales, revenue, price, market share of each type, can be divided into • 0.30 mg • 0.15 mg Split by applications, this report focuses on sales, market share and growth rate of Epinephrine Autoinjector in each application, can be divided into • Under 6 Years Patients • 6 to 12 Years Patients • Over 12 Years Patients Purchase a copy of this report at: https://www.themarketreports.com/report/buy-now/477084 1 Epinephrine Autoinjector Market Overview 2 Global Epinephrine Autoinjector Sales, Revenue (Value) and Market Share by Manufacturers 3 Global Epinephrine Autoinjector Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 4 Global Epinephrine Autoinjector Manufacturers Profiles/Analysis 5 North America Epinephrine Autoinjector Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 6 Latin America Epinephrine Autoinjector Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 7 Europe Epinephrine Autoinjector Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 8 Asia-Pacific Epinephrine Autoinjector Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 9 Middle East and Africa Epinephrine Autoinjector Sales, Revenue (Value) by Countries, Type and Application (2012-2017) 10 Epinephrine Autoinjector Manufacturing Cost Analysis 11 Industrial Chain, Sourcing Strategy and Downstream Buyers 12 Marketing Strategy Analysis, Distributors/Traders 13 Market Effect Factors Analysis 14 Global Epinephrine Autoinjector Market Forecast (2017-2022) 15 Research Findings and Conclusion 16 Appendix Inquire more for more details about this report at: https://www.themarketreports.com/report/ask-your-query/477084 For more information, please visit https://www.themarketreports.com/report/2017-2022-global-top-countries-epinephrine-autoinjector-market-report-94444202%20


Tabar A.I.,Hospital Virgen Del Camino | Arroabarren E.,Hospital Universitario Donostia | Echechipia S.,Hospital Virgen Del Camino | Garcia B.E.,Hospital Virgen Del Camino | And 2 more authors.
Journal of Allergy and Clinical Immunology | Year: 2011

Background: Specific immunotherapy (SIT) duration for respiratory allergy is currently based on individual decisions. Objective: To evaluate the differences in clinical efficacy of SIT as a result of the duration between the current recommended limits (3-5 years). Methods: A 5-year prospective, controlled clinical trial of SIT blind until the first year and randomization to a 3-year (IT3) or 5-year (IT5) course was conducted. Of the 239 patients with respiratory allergy caused by D pteronyssinus initially included, 142 completed 3 years of SIT with good compliance. Twenty-seven controls were included at the third year. Efficacy of SIT after 3 (T3) and 5 (T5) years was assessed by using clinical scores, visual analog scales (VASs), rhinitis (RQLQ) and asthma (AQLQ) quality of life questionnaires, skin tests, and serum immunoglobulins. Results: At T3, significant reductions were observed in rhinitis (44% in IT3 and 50% in IT5; P < .001), asthma (80.9 % in IT3 and 70.9% in IT5; P < .001) scores, VAS (P < .001 in both), RQLQ (P < .001 in both) and AQLQ (P < .001 in both). At T5, the clinical benefit was maintained in both groups, and IT5 patients presented additional decreases (19%; P = .019) in rhinitis scores. At Tf, specific IgG 4 measurements were lower in IT3 (P = .03) without detecting differences in IT5. An increase in asthma score of 133% was the only difference observed in controls. Conclusion: Clinical improvement is obtained with 3 years of D pteronyssinus SIT. Two additional years of SIT add clinical benefit in rhinitis only. © 2010 American Academy of Allergy, Asthma & Immunology.


Suarez-Fueyo A.,CSIC - National Center for Biotechnology | Ramos T.,Hospital Universitario Of La Princesa Ip | Galan A.,ALK Abello | Jimeno L.,ALK Abello | And 7 more authors.
Journal of Allergy and Clinical Immunology | Year: 2014

Background Sublingual administration of Phleum pratense allergen immunotherapy (SLIT) tablets is a clinically efficient treatment for grass pollen-induced rhinoconjunctivitis. This immunotherapy downregulates T H2 immune responses, induces tolerogenic pathways, and increases regulatory T cells. However, associated immune response markers of allergen desensitization remain undefined. Objective We sought to characterize the kinetics of individual changes in the immunologic response to grass tablet SLIT. Methods We evaluated the systemic effects of SLIT in a longitudinal analysis of humoral and cellular immune parameters in peripheral blood samples. Results Grass tablet SLIT administration induced a 2-phase systemic humoral and cellular response. The TH2 response was initially exacerbated and detected as increased allergen-specific IgE (sIgE) and IgG4 (sIgG4) levels and an increase in IL-4-producing cells, followed by downregulation of the TH2 response with a shift toward a TH1 cytokine profile. T cells with a regulatory phenotype were also elicited. Statistical correlations between immunologic measurements for each patient throughout therapy indicated that TH2 response downregulation and reduction of the immediate SLIT-induced IgE response were associated with increased allergen-specific IgG4 synthesis early in therapy. TH2 response downregulation by month 4 correlated with increased frequency of CD4+ T cells with a regulatory phenotype by 12 months. Conclusion Changes in sIgE levels after therapy were linked to a specific IgG4 response, and production of blocking antibodies correlated with TH2 response downregulation. Reduced IL-4+ cell frequency was linked to an increase in the frequency of CD4+ T cells with a regulatory phenotype. Changes in sIgE levels and reduced IL-4 and blocking antibody levels could thus be used as indicators of a patient's immune response to therapy. © 2013 American Academy of Allergy, Asthma & Immunology.


Sastre J.,Fundacion Jimenez Diaz | Rodriguez F.,Hospital Marques Of Valdecilla | Campo P.,Hospital Carlos Haya | Laffond E.,Hospital Universitario Of Salamanca | Marin A.,ALK Abello
Allergy: European Journal of Allergy and Clinical Immunology | Year: 2015

The aim of the study was to investigate whether adverse drug reactions (ADRs) during immunotherapy with a grass extract (AVANZ® Phleum, ALK-Abelló) are related to the different patterns of sensitization of patients to grass allergens. A total of 192 patients with rhinitis and/or asthma sensitized to grass pollen received a 4-week updosing with five injections. ADRs were evaluated following EAACI guidelines. A total of 432 ADRs in 133 (69%) patients were recorded, 64% local and 31% systemic. There was a significant association between the number of grass allergens that sensitized the patients and the total number of ADRs (P = 0.004) occurred locally (P = 0.003) and systemically (P = 0.01). Sensitization to Phl p1 + Phl p5 or Phl p1 + Phl p5 + Phl p12 was significantly associated with a higher frequency of local or systemic reactions (P = 0.001, both). Different patterns of sensitization to grass allergens may potentially be considered a risk marker to the development of ADRs to immunotherapy. © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.


Esch R.E.,Greer Laboratories | Plunkett G.A.,ALK Abello
Current Allergy and Asthma Reports | Year: 2013

Allergen immunotherapy has been used to treat allergic diseases for more than 100 years. In the U.S., the preparation of diagnostic and therapeutic extracts requires the cooperation of the extract manufacturer, who provides the individual allergen concentrates, and the practicing physician who formulates, dilutes, and administers the final patient-specific treatment extract. The guidelines, rules, and regulations for these activities have been established and continue to be developed as progress is made. The molecular characterization and standardization of allergenic extracts has allowed for improvements in defining the potency of these products. In turn, these advances have led to improved dosing regimens and formulation practices. This review will describe in detail some of these interactions and will identify issues that require more attention. © 2013 Springer Science+Business Media New York.


News Article | December 6, 2016
Site: www.newsmaker.com.au

According to Stratistics MRC, the Global Auto Injectors Market is accounted for $1.10 billion in 2015 and is expected to reach $3.78 billion by 2022 growing at a CAGR of 19.42%. As large number of patients are opting of self administered treatment and care there is a flawless increase in use of Auto Injectors market. Moreover, the high prevailing patients of anaphylaxis had presented a huge demand for the market which seems as pertaining factor behind the market growth. At the same time high cost and need for utmost care are some of the factors dumping the market down at certain period of time. Prefilled Syringes in primary drug container segment seems to be predominant in market segment because of the dramatic effect on the way injectable drugs are developed, prescribed and administered. Anaphylaxis in the therapeutic application segment will be dominant throughout the forecast period, as more people are allergic and nauseous. While North America being the largest market, Asia pacific hails as fastest growing because of channeling investments into China and India and improving consumer awareness through marketing campaigns. Some of the major key players of the market are Unilife Corporation, Novartis International AG, Becton, Dickinson and Company, Antares Pharma, Inc., Mylan, Inc., Adamis Pharmaceuticals Corp, Hospira Inc, Scandinavian Health Limited (SHL) Group, Sanofi SA, Itelliject Inc , Pfizer, Inc., Lincoln Medical Ltd, Ypsomed Holdings AG, ALK Abello, Teva Pharmaceuticals Ltd and Biogen Idec, Inc. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK  o Spain   o Rest of Europe     • Asia Pacific o Japan        o China        o India        o Australia        o New Zealand       o Rest of Asia Pacific     •  Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements


News Article | February 20, 2017
Site: marketersmedia.com

Wiseguyreports.Com Adds “Epinephrine Autoinjector -Market Demand, Growth, Opportunities and analysis of Top Key Player Forecast to 2021” To Its Research Database The Global Epinephrine Autoinjector Industry 2016 Market Research Report is a professional and in-depth study on the current state of the epinephrine autoinjector industry. Firstly, the report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The epinephrine autoinjector market analysis is provided for the international market including development history, competitive landscape analysis, and major regions’ development status. Secondly, development policies and plans are discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin by regions (North America, Europe and Asia), and other regions can be added. Then, the report focuses on global major leading industry players with information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Upstream raw materials, equipment and downstream consumers analysis is also carried out. What’s more, the epinephrine autoinjector industry development trends and marketing channels are analyzed. Finally, the feasibility of new investment projects is assessed, and overall research conclusions are offered. In a word, the report provides major statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. 1 Industry Overview of Epinephrine Autoinjector 1 1.1 Definition and Specifications of Epinephrine Autoinjector 1 1.1.1 Definition of Epinephrine Autoinjector 1 1.1.2 Trademarks of Epinephrine Autoinjector 2 1.2 Classification of Epinephrine Autoinjector 4 1.2.1 0.30 mg Epinephrine Autoinjector 5 1.2.2 0.15 mg Epinephrine Autoinjector 5 1.3 Applications of Epinephrine Autoinjector 6 1.3.1 Under 6 Years Patients 7 1.3.2 6 to 12 Years 8 1.3.3 Over 12 Years 8 1.4 Industry Chain Structure of Epinephrine Autoinjector 9 1.5 Industry Overview and Major Regions Status of Epinephrine Autoinjector 10 1.5.1 Industry Overview of Epinephrine Autoinjector 10 1.5.2 Global Major Regions Status of Epinephrine Autoinjector 11 1.6 Industry Policy Analysis of Epinephrine Autoinjector 11 1.7 Industry News Analysis of Epinephrine Autoinjector 14 4 Capacity, Production and Revenue Analysis of Epinephrine Autoinjector by Region, Type and Manufacturer 24 5 Price, Cost, Gross and Gross Margin Analysis of Epinephrine Autoinjector by Region, Types and Manufacturers 44 6 Consumption Volume, Consumption Value and Sale Price Analysis of Epinephrine Autoinjector by Region, Type and Application 50 8 Analysis of Epinephrine Autoinjector Industry Key Manufacturers 73 8.1 Mylan 73 8.1.1 Company Profile 73 8.1.2 Product Information 75 8.1.3 Capacity, Production, Price, Cost, Gross, and Revenue 76 8.2 Sanofi 77 8.2.1 Company Profile 77 8.2.2 Product Information 79 8.2.3 Capacity, Production, Price, Cost, Gross, and Revenue 79 8.3 ALK Abello 81 8.3.1 Company Profile 81 8.3.2 Product Information 83 8.3.3 Capacity, Production, Price, Cost, Gross, and Revenue 83 8.4 Impax 85 8.4.1 Company Profile 85 8.4.2 Product Information 87 8.4.3 Capacity, Production, Price, Cost, Gross, and Revenue 87 For more information, please visit https://www.wiseguyreports.com/sample-request/531432-global-epinephrine-autoinjector-industry-2016-market-research-report


Senna G.E.,Unita Operativa di Allergologia Ospedale Civile Maggiore di Verona | Calderon M.,Imperial College London | Milani M.,ALK Abello
Expert Review of Clinical Immunology | Year: 2011

Immunotherapy is the only treatment for allergy that alters the natural course of this disease. Sublingual immunotherapy has been developed to make immunotherapy more suitable for allergic patients. In the largest clinical program ever conducted with grass allergen-specific immunotherapy, over 2000 adults and more than 500 children have been exposed to Grazax® (ALK-Abello A/S, Hoersholm, Denmark). Grazax is an oral lyophilisate tablet (allergy immunotherapy tablet [AIT]) for sublingual administration, containing 75,000 standardized quality tablet units of allergen extract of grass pollen (Phleum pratense). Grazax is indicated for treatment of grass pollen-induced rhinitis and conjunctivitis in adult and pediatric patients. Results from the GT-08 trial (first, second and third treatment years) showed a reduction of 31, 36 and 29%, respectively, in symptom scores and a reduction of 38, 45 and 40% of medication scores, respectively, compared with placebo. Subjects treated with Grazax also had an increased number of well days and a relevant improvement in quality of life. More subjects experienced excellent and complete rhinoconjunctivitis control in comparison with patients treated with symptomatic medications only. Grazax treatment is also associated with a sustained and relevant increase of specific IgG4. This increase is also observed after stopping AIT treatment. The most common adverse events related to Grazax treatment are local reactions, such as oral itch, edema of the mouth, ear pruritus, throat irritation and sneezing. Clinical efficacy of Grazax is observed also after 1 and 2 years of follow-up after stopping the AIT treatment. Grazax is efficacious and safe for treatment of grass-pollen rhinoconjunctivitis in both adults and children. Grazax is the first AIT showing a disease-modifying effect on grass pollen-induced allergic rhinoconjuctivitis. © 2011 Expert Reviews Ltd.


Asero R.,Ambulatorio di Allergologia | Jimeno L.,ALK Abello | Barber D.,ALK Abello
Journal of Investigational Allergology and Clinical Immunology | Year: 2010

Background: Calcium-binding proteins (polcalcins) and profilin are cross-reacting panallergens that sensitize a minority of pollen-allergic patients. Their clinical relevance remains controversial. Objective: To assess the clinical relevance of hypersensitivity to polcalcin and profilin detected by skin prick test (SPT) in a large group of pollen-allergic patients. Methods: Two hundred pollen-allergic adults (101 men, 99 women; mean age 34 years) underwent SPT with 9 pollens present in the geographical area of the study. Hypersensitivity to panallergens was detected by SPT with date palm polcalcin and profilin. Allergy to birch and/or cypress, grass and/or pellitory, and ragweed and/or mugwort were associated with 3 symptomatic periods, respectively, late February to mid-May, late April to mid-July, and mid-August to late September. Results: Sixteen (8%) patients reacted to date palm polcalcin; 7/7 (100%) corecognized the grass polcalcin Phl p 7 in vitro. Clinically, only 4 (25%) had symptoms in all 3 seasonal periods. Forty (20%) patients reacted to profilin; only 32 (80%) reacted to cypress, and 22 (55%) to pellitory. Only 4 (10%) patients had symptoms during all 3 seasonal periods. Six patients (3%) were cosensitized to both polcalcin and profilin. Conclusions: The clinical relevance of hypersensitivity to pollen panallergens is often limited; many allergic patients have symptoms only during the central period, suggesting primary grass sensitization. Profilin-allergic patients often do not corecognize pellitory and cypress pollen. In vivo component-resolved diagnosis of seasonal respiratory allergies is a promising approach that might lead to cost reduction and a faster definition of pollen-allergic cases. © 2010 Esmon Publicidad.


Holm J.,ALK Abello | Willumsen N.,ALK Abello | Wurtzen P.A.,ALK Abello | Christensen L.H.,ALK Abello | Lund K.,ALK Abello
Journal of Allergy and Clinical Immunology | Year: 2011

Background: The antibody repertoires of allergic subjects are characterized by the presence of allergen-specific IgE antibodies. We have previously shown that the composition of the IgE repertoire is critical for allergen-mediated activation of human effector cells. Activation of CD4+ T cells in allergic subjects is highly potentiated by the process of facilitated antigen presentation (FAP), in which allergen in complex with IgE is taken up by B cells through the low-affinity IgE receptor CD23 and presented to T cells. Objective: We sought to investigate the influence of IgE repertoire complexity on the formation of IgE/allergen/CD23 complexes on B cells and subsequent T-cell activation. Methods: Using defined allergen-specific recombinant IgE and IgG antibodies, we investigated the influence of individual IgE affinity, IgE clonality, specific IgE concentration, and the ratio between IgE specificities on IgE/allergen/CD23 complex formation in vitro. Results: Although IgE affinity is an important factor, IgE clonality seems to be governing complex formation, especially with medium- and low-affinity IgE antibodies. We demonstrate that differences in allergen-specific IgE affinity correlate with the efficiency of subsequent T-cell activation. In addition, we show that the complexity of an IgE repertoire also affects the ability of allergen-specific IgG antibodies to block FAP. Conclusion: The composition of allergen-specific IgE repertoires in individual patients, especially with respect to IgE clonality, might play an important role in the manifestation of allergic disease not only for the immediate allergic reaction through activation of basophils and mast cells but also for the exacerbation of allergic inflammation through recurring activation of allergen-specific T cells by FAP. © 2010 American Academy of Allergy, Asthma & Immunology.

Loading ALK Abello collaborators
Loading ALK Abello collaborators